Shionogi Seeks Approval for Rapid-Acting Depression Drug

Shionogi & Co (JP:4507) has released an update.

Shionogi & Co., a leading global pharmaceutical company, has submitted a New Drug Application in Japan for zuranolone, a promising treatment for major depressive disorder (MDD) with rapid efficacy demonstrated in clinical trials. This novel therapy offers potential benefits for the estimated 5 million patients suffering from depression in Japan, where current treatments often have delayed onset. Zuranolone, already approved in the U.S. for postpartum depression, is a neuroactive steroid expected to rapidly alleviate symptoms without the need for dose adjustment.

For further insights into JP:4507 stock, check out TipRanks’ Stock Analysis page.